308 related articles for article (PubMed ID: 18053228)
1. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Hartz I; Sakshaug S; Furu K; Engeland A; Eggen AE; Njølstad I; Skurtveit S
BMC Clin Pharmacol; 2007 Dec; 7():14. PubMed ID: 18053228
[TBL] [Abstract][Full Text] [Related]
2. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
4. Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
Sakshaug S; Furu K; Karlstad Ø; Rønning M; Skurtveit S
Br J Clin Pharmacol; 2007 Oct; 64(4):476-81. PubMed ID: 17441934
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
7. Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.
Halava H; Helin-Salmivaara A; Junnila J; Huupponen R
Eur J Clin Pharmacol; 2009 Sep; 65(9):927-33. PubMed ID: 19471912
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Hilleman DE; Wurdeman RL; Lenz TL
Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
[TBL] [Abstract][Full Text] [Related]
9. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
Devold HM; Molden E; Skurtveit S; Furu K
Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
11. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Tungsubutra W; Phongtuntakul B
J Med Assoc Thai; 2015 Feb; 98(2):129-36. PubMed ID: 25842792
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
Bożentowicz-Wikarek M; Kocełak P; Smertka M; Olszanecka-Glinianowicz M; Chudek J
Pharmacol Rep; 2012; 64(2):377-85. PubMed ID: 22661189
[TBL] [Abstract][Full Text] [Related]
13. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
14. Differences between statins on clinical endpoints: a population-based cohort study.
Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
[TBL] [Abstract][Full Text] [Related]
15. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Curr Med Res Opin; 2008 Jul; 24(7):1987-2000. PubMed ID: 18554430
[TBL] [Abstract][Full Text] [Related]
16. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
17. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
[TBL] [Abstract][Full Text] [Related]
18. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
19. Impact of high dose statin trials on hospital prescribers.
Barron TI; Bennett K; Feely J
Eur J Clin Pharmacol; 2007 Jan; 63(1):65-72. PubMed ID: 17115149
[TBL] [Abstract][Full Text] [Related]
20. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
Simonyi G
Orv Hetil; 2014 Apr; 155(17):669-75. PubMed ID: 24755449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
